MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-20-2026
Abbott Laboratories Cost of Revenue 2011-2026 | ABT
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Abbott Laboratories
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 19.3 B | 18.7 B | 18 B | 19.1 B | 18.5 B | 15 B | 13.2 B | 12.7 B | 12.4 B | 9.09 B | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 19.3 B | 9.09 B | 15.6 B |
Quarterly Cost of Revenue Abbott Laboratories
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.85 B | 4.47 B | 4.7 B | 4.6 B | 4.46 B | 4.6 B | 4.48 B | 4.33 B | - | 4.63 B | 4.93 B | 4.99 B | - | 4.42 B | 4.95 B | 4.4 B | - | 3.97 B | 3.26 B | 3.28 B | - | 3.36 B | 3.28 B | 3.16 B | - | 3.17 B | 3.28 B | 3.07 B | - | 2.88 B | 3.19 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 4.99 B | 2.88 B | 4.03 B |
Cost of Revenue of other stocks in the Medical devices industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Acutus Medical
AFIB
|
10.3 M | - | -26.83 % | $ 2.62 M |  USA |
 |
Alphatec Holdings
ATEC
|
232 M | $ 13.73 | -2.21 % | $ 2.06 B | USA |
 |
Allied Healthcare Products
AHPI
|
24.5 M | - | 3.58 % | $ 2.21 M | USA |
 |
Apollo Endosurgery
APEN
|
34.4 M | - | - | $ 475 M | USA |
 |
Avinger
AVGR
|
5.65 M | - | -20.74 % | $ 369 K | USA |
 |
AxoGen
AXGN
|
57.9 M | $ 31.12 | -0.34 % | $ 1.43 B | USA |
 |
Axonics Modulation Technologies
AXNX
|
76 M | - | - | $ 3.31 B | USA |
 |
Cognyte Software Ltd.
CGNT
|
104 M | $ 6.82 | 2.95 % | $ 490 M |  Israel |
 |
Aziyo Biologics
AZYO
|
13.7 M | - | 1.37 % | $ 20.5 M | USA |
 |
Apyx Medical Corporation
APYX
|
18.6 M | $ 3.44 | 0.58 % | $ 119 M | USA |
 |
Conformis
CFMS
|
38.8 M | - | - | $ 16.4 M | USA |
 |
ClearPoint Neuro
CLPT
|
12.3 M | $ 12.98 | -14.39 % | $ 351 M | USA |
 |
Bio-Rad Laboratories
BIO
|
1.19 B | $ 270.55 | 0.41 % | $ 7.63 B | USA |
 |
BIOLASE
BIOL
|
32.4 M | - | -13.19 % | $ 166 K | USA |
 |
Bruker Corporation
BRKR
|
1.72 B | $ 39.83 | -0.15 % | $ 5.94 K | USA |
 |
BioSig Technologies
BSGM
|
57 K | - | 37.08 % | $ 85.7 M | USA |
 |
Boston Scientific Corporation
BSX
|
6.22 B | $ 74.69 | 1.66 % | $ 111 B | USA |
 |
EDAP TMS S.A.
EDAP
|
37.6 M | $ 4.5 | -1.96 % | $ 168 M |  France |
 |
Electromed
ELMD
|
14 M | $ 24.17 | 1.05 % | $ 204 M | USA |
 |
CONMED Corporation
CNMD
|
624 M | $ 46.25 | 0.61 % | $ 1.44 B | USA |
 |
Cardiovascular Systems
CSII
|
63.4 M | - | 0.15 % | $ 844 M | USA |
 |
Neovasc
NVCN
|
556 K | - | - | $ 111 M |  Canada |
 |
Cutera
CUTR
|
171 M | - | -10.19 % | $ 1.99 M | USA |
 |
Delcath Systems
DCTH
|
6.19 M | $ 9.28 | -9.16 % | $ 265 M | USA |
 |
Dynatronics Corporation
DYNT
|
21.4 M | - | 14.99 % | $ 929 K | USA |
 |
Eargo
EAR
|
23 M | - | - | $ 10.2 M | USA |
 |
InMode Ltd.
INMD
|
79.5 M | $ 13.91 | -0.39 % | $ 899 M | Israel |
 |
Second Sight Medical Products
EYES
|
11.8 M | - | -0.97 % | $ 54.4 M | USA |
 |
IRIDEX Corporation
IRIX
|
30.1 M | $ 1.47 | -2.0 % | $ 23.7 M | USA |
 |
IRadimed Corporation
IRMD
|
16.9 M | $ 100.65 | 0.15 % | $ 1.28 B | USA |
 |
Establishment Labs Holdings
ESTA
|
56.5 M | $ 75.32 | -3.79 % | $ 2.12 B |  Costa-rica |
 |
GBS
GBS
|
1.81 M | - | -0.57 % | $ 7.12 M | USA |
 |
LivaNova PLC
LIVN
|
448 M | $ 70.57 | 0.4 % | $ 3.85 B |  Britain |
 |
Globus Medical
GMED
|
958 M | $ 95.47 | -0.77 % | $ 12.9 B | USA |
 |
Medtronic PLC
MDT
|
11.6 B | $ 96.23 | -0.44 % | $ 124 B | USA |
 |
MiMedx Group
MDXG
|
73 M | $ 4.89 | -7.48 % | $ 723 M | USA |
 |
Pulmonx Corporation
LUNG
|
21.8 M | $ 1.56 | -4.6 % | $ 61 M | USA |
 |
Helius Medical Technologies
HSDT
|
583 K | $ 1.91 | -12.07 % | $ 1.16 M | USA |
 |
Invacare Corporation
IVC
|
566 M | - | - | $ 24.7 M | USA |